Oxford Scientists Launch Human Trials of New Ebola Vaccine Amid Escalating Congo Outbreak

Scientists at the University of Oxford are preparing to begin human trials of a promising new vaccine designed to protect against the Bundibugyo strain of Ebola, as health authorities race to contain a deadly outbreak in the Democratic Republic of Congo (DRC).

The clinical trial, expected to commence in the coming weeks pending regulatory approval, will assess the vaccine’s safety and ability to trigger an immune response in 50 healthy volunteers aged between 18 and 55 years in the United Kingdom.

The vaccine, known as ChAdOx1 BDBV, was developed in record time following the World Health Organization’s (WHO) declaration of the Bundibugyo Ebola outbreak as a Public Health Emergency of International Concern on May 17. Remarkably, the candidate vaccine reached the trial stage in just 57 days, highlighting the speed of modern vaccine research and global scientific collaboration.

Researchers revealed that 620,000 doses of the vaccine have already been manufactured and stockpiled for potential emergency use, while 4,000 investigational doses have been allocated specifically for the Oxford clinical trial.
One major advantage of the vaccine is that it uses the same ChAdOx viral vector technology employed in the widely used Oxford/AstraZeneca COVID-19 vaccine, enabling scientists to accelerate its development and production.

Professor Teresa Lambe, the study’s lead scientific investigator, said the worsening Ebola outbreak underscores the urgent need for effective vaccines.
“The ongoing Bundibugyo ebolavirus outbreak continues to devastate affected communities, underlining the urgent need for effective vaccines and treatments,” she said.

She added that the rapid development of the vaccine demonstrates the value of strong international scientific partnerships in responding swiftly to emerging health emergencies.

The outbreak continues to worsen. According to the latest figures released on Monday, the DRC has recorded 1,926 confirmed Ebola cases, including 702 deaths, making the search for an effective vaccine increasingly urgent.

Health experts believe that if the vaccine proves safe and effective during the trial, it could become an important tool in controlling future outbreaks of the Bundibugyo strain, one of the less common but highly dangerous forms of the Ebola virus.

The Oxford trial represents another significant step in global efforts to strengthen preparedness against emerging infectious diseases and prevent future public health crises.